SeaStar Medical Holding opened lower at $1.21, compared with its previous close of $1.92. In the last trading session, the stock traded between $0.98 and $1.31. It showed a downward intraday trend.
An investment of $100 made 5 years ago in SeaStar Medical Holding is now worth
$ 0.04
Resulting in a loss of
$ 99.96 (99.96%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
$-0.87 (-45.05%)
Day High
$1.31
Day Low
$0.98
Day Open
$1.21
Prev Close
$1.92
Volume
7,89,435
1W Return
-48.16%
1M Return
-72.51%
3M Return
-71.21%
6M Return
-76.97%
1Y Return
-78.47%
Market Cap ($ Mn)
6
PE Ratio
-
PB Ratio
3.08
PEG Ratio
-
ROE
-257.38%
ROCE
-263.55%
EPS (TTM)
$-0.83
1 Week
-48.16%
1 Month
-72.51%
3 Months
-71.21%
6 Months
-76.97%
9 Months
-54.91%
SeaStar Medical Q3 revenue up 247% to $635k; loss widens to $4.5m
SeaStar Medical reported Q3FY26 net revenue of $635,000, up 247% YoY. Net loss widened to $4.5 million ($1.03 per share) from $3.5 million. R&D expenses rose to $3.6 million due to NEUTRALIZE-AKI trial activities. Cash reserves declined to $4 million from $12 million at end of FY25.
YesterdaySeaStar Medical to report Q3FY27 results on November 11
SeaStar Medical will release third quarter financial results on November 11, 2026. Earnings call scheduled for 4:30 pm ET with mandatory preregistration. Company highlights FDA-approved pediatric product and ongoing adult clinical trials.
8 days agoFDA confirms SeaStar Medical fulfilled QUELIMMUNE study requirements
FDA CBER confirmed QUELIMMUNE Pediatric SAVE Registry fulfilled post-approval study requirements. Removal of research infrastructure mandate expands potential hospital adoption for pediatric AKI. Registry data showed 65.1% 90-day survival rate versus 47.5% in control cohort.
9 days agoSeaStar Medical CMO named 2026 Combat Nephrology Award recipient
Kevin Chung named 2026 Combat Nephrology Award recipient for combat casualty care expertise. QUELIMMUNE therapy showed 77% survival rate in clinical trials versus standard of care. SAVE Registry data indicates 76% survival rate at Day 28 and Day 60 in pediatric patients. NEUTRALIZE-AKI pivotal trial currently evaluating SCD therapy in 339 adult AKI patients.
29 days agoSeaStar Medical secures new ICD-10-PCS codes for SCD therapy
New ICD-10-PCS codes effective October 1, 2026, enable hospital billing for SeaStar Medical's SCD therapy. Codes cover intermittent, prolonged intermittent, and continuous urinary filtration with selective cytopheresis. QUELIMMUNE clinical data shows 77% survival rate versus standard of care in pediatric AKI patients. New coding framework supports potential future adoption for adult AKI patients pending regulatory approval.
1mo agoSeaStar Medical CEO to present at HC Wainwright investment conference
SeaStar Medical CEO Eric Schlorff to present at HC Wainwright conference. Event scheduled for September 14-16, 2026, in New York City. Presentation available online starting September 11, 2026. QUELIMMUNE remains only FDA-approved product for pediatric AKI due to sepsis. NEUTRALIZE-AKI trial ongoing for adult AKI patients.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in SeaStar Medical Holding is now worth
$ 0.04
Resulting in a loss of
$ 99.96 (99.96%)
Note: Past profits do not guarantee future returns.
